3430-14-6

Basic information

• Product Name: 5-Amino-2-methylpyridine
• Synonyms: 6-Methylpyridin-3-amine, 5-Amino-2-picoline;5-Amino-2-methylpyridine,97%;5-Amino-2-methypyridine;5-Amino-2-methylpyridine 97%;6-METHYL-PYRIDIN-3-YLAMINE;5-AMINO-2-METHYLPYRIDINE;5-AMINO-2-PICOLINE;3-AMINO-6-PICOLINE
• CAS NO: 3430-14-6
• Molecular Formula: C₆H₈N₂
• Molecular Weight: 108.14
• EINECS: -0
• Product Categories: VARIOUSAMINE;pyridines;Pyridine;Pyridine Series;Amines;Pyridines derivates
• Mol File: 3430-14-6.mol
• Article Data: 13

Chemical Properties

• Melting Point: 95-99°C
• Boiling Point: 238.419 °C at 760 mmHg
• Flash Point: 121.09 °C
• Appearance: Off-white to orange to brown/Powder
• Density: 1.068 g/cm³
• Vapor Pressure: 0.042mmHg at 25°C
• Refractive Index: 1.574
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 6.89±0.10(Predicted)
• CAS DataBase Reference: 5-Amino-2-methylpyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-Amino-2-methylpyridine(3430-14-6)
• EPA Substance Registry System: 5-Amino-2-methylpyridine(3430-14-6)

Safety Data

• Hazard Codes: Xn,Xi,C
• Statements: 22-37/38-41-36/37/38-34-24/25
• Safety Statements: 26-36/39-45-36/37/39-36-27-36/37
• RIDADR: UN2811
• WGK Germany: 3
• HazardClass: 6.1
• PackingGroup: III
• Hazardous Substances Data: 3430-14-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
5-Amino-2-methylpyridine is used as a heterocyclic building block for the synthesis of various pharmaceutical compounds. Its unique structure allows for the creation of diverse molecules with potential therapeutic properties.
Used in the Synthesis of 2-Aminoquinazoline Derivatives:
5-Amino-2-methylpyridine is used as a key intermediate in the synthesis of 2-aminoquinazoline derivatives. These derivatives have been identified as a novel class of metabotropic glutamate receptor 5 (mGluR5) negative allosteric modulators, which are potential drug candidates for the treatment of l-DOPA induced dyskinesia, a movement disorder commonly associated with long-term use of l-DOPA in Parkinson's disease patients.

InChI:InChI=1/C6H8N2/c1-5-2-3-6(7)4-8-5/h2-4H,7H2,1H3

Upstream product

• 21203-68-9 2-methyl-5-nitropyridine 
• 7440-44-0 pyrographite 
• 2280-44-6 D-Glucose 
• 76809-31-9 2,2-dimethyl-3-(2-methylpyrid-5-yl)-4-oxo-4H-1,3-benzoxazine 

Downstream Products

• 31181-53-0 2‐methyl‐5‐fluoropyridine 
• 126325-53-9 3-amino-2-bromo-6-methylpyridine 
• 5000-80-6 2-[(6-methyl-pyridin-3-ylamino)-methylene]-malonic acid diethyl ester 
• 1150618-39-5 cis/trans-tert-butyl (6-methylpiperidin-3-yl)carbamate 
• 1405129-10-3 tert-butyl ((3R,6R)-1-(3-((2-(2,6-difluorophenyl)imidazo[1,5-b]pyridazin-7-yl)amino)pyridin-4-yl)-6-methylpiperidin-3-yl)carbamate 
• 1405129-11-4 tert-butyl ((3S,6R)-1-(3-((2-(2,6-difluorophenyl)imidazo[1,5-b]pyridazin-7-yl)amino)pyridin-4-yl)-6-methylpiperidin-3-yl)carbamate 
• 1405129-12-5 tert-butyl ((3R,6S)-1-(3-((2-(2,6-difluorophenyl)imidazo[1,5-b]pyridazin-7-yl)amino)pyridin-4-yl)-6-methylpiperidin-3-yl)carbamate 
• 1405129-09-0 tert-butyl ((3S,6S)-1-(3-((2-(2,6-difluorophenyl)imidazo[1,5-b]pyridazin-7-yl)amino)pyridin-4-yl)-6-methylpiperidin-3-yl)carbamate 
• 1222491-53-3 1,1-dimethylethyl [6-methyl-3-piperidinyl]carbamate 
• 1222491-53-3 trans-tert-butyl N-(6-methyl-3-piperidyl)carbamate 
• 1566543-16-5 2-(2-(2-(5-chloro-2-(6-methylpyridin-3-ylamino)pyrimidin-4-yl)ethyl)phenyl)propanamide 
• 1442474-57-8 1-(5-(1-ethyl-7-((6-methylpyridin-3-yl)amino)-2-oxo-1,2-dihydro-1,6-naphthyridin-3-yl)-2-fluoro-4-methylphenyl)-3-phenylurea 
• 3256-88-0 5-phenyl-2-picoline 

Relevant articles and documents

Process Development and Protein Engineering Enhanced Nitroreductase-Catalyzed Reduction of 2-Methyl-5-nitro-pyridine

Reduction of aromatic nitro compounds to anilines is of great interest to the chemical industry. Biocatalytic reduction of nitroarenes has made it possible to effectively produce anilines by applying nitroreductase enzymes (NR) in combination with vanadium pentoxide. Herein, the NR-catalyzed reduction of 2-methyl-5-nitro-pyridine (2) to give the desired aniline (1) was studied as a model reaction. It demonstrates the importance of process development and enzyme engineering as key approaches to overcome scale-up issues and improve yield and productivity. Moving to fed-batch allowed controlling the feeding rate of 2 to prevent the accumulation of intermediates and formation of undesired side products. Starting with a substrate (2) concentration of 200 mM (28 g/L) and enzyme loading of 5 mg/mL (18% w/w), it was possible to achieve complete conversion and 1 in 95% yield by high-performance liquid chromatography (89.1% isolated yield) over 18 h, whereas, with 500 mM (69 g/L) 2 and an enzyme loading of 10 mg/mL (14.5% w/w), the same conversion and yield were achieved in 26 h. A rational engineering of NR-4 yielded faster variants, including NR-5, in only one round. The improved rate of the new variants allowed increasing the feeding rate of 2 to shorten the reaction time to less than a day as well as decreasing the enzyme loading to 3.6%.

SYNTHESIS OF OMECAMTIV MECARBIL

Provided herein is a synthesis for omecamtiv mecarbil dihydrochloride hydrate and various intermediates. (I)

ARYL-SULFONAMIDE AND ARYL-SULFONE DERIVATIVES AS TRPML MODULATORS

The new arylsulfonamide and arylsulfone derivatives are modulators of TRPML and are useful in treating disorders related to TRPML activities and lysosome functions such as acid-related disorders and cancer.

SUBSTITUTED TRIAZOLE DERIVATIVES AS OXYTOCIN ANTAGONISTS

The present invention relates to a class of substituted triazoles of formula (I) with activity as oxytocin antagonists, uses thereof, processes for the preparation thereof and compositions containing said inhibitors. These inhibitors have utility in a variety of therapeutic areas including sexual dysfunction, particularly premature ejaculation (P.E.).

Structure-Activity Relationships of the p38α MAP Kinase Inhibitor 1-(5-tert-Butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy) naphthalen-1-yl]urea (BIRB 796)

We report on the structure-activity relationships (SAR) of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy) naphthalen-1-yl]urea (BIRB 796), an inhibitor of p38α MAP kinase which has advanced into human clinical trials for the treatment of autoimmune diseases. Thermal denaturation was used to establish molecular binding affinities for this class of p38α inhibitors. The tert-butyl group remains a critical binding element by occupying a lipophilic domain in the kinase which is exposed upon rearrangement of the activation loop. An aromatic ring attached to N-2 of the pyrazole nucleus provides important π-CH 2 interactions with the kinase. The role of groups attached through an ethoxy group to the 4-position of the naphthalene and directed into the ATP-binding domain is elucidated. Pharmacophores with good hydrogen bonding potential, such as morpholine, pyridine, and imidazole, shift the melting temperature of p38α by 16-17 °C translating into Kd values of 50-100 pM. Finally, we describe several compounds that potently inhibit TNF-α production when dosed orally in mice.

1,4-Benzofused urea compounds useful in treating cytokine mediated diseases

Disclosed are 1,4-disubstituted benzo-fused urea compounds of formula (I): wherein Ar, X, A, L, and Q of formula(I) are defined herein. The compounds inhibit production of cytokines involved in inflammatory processes and are thus useful for treating diseases and pathological conditions involving inflammation such as chronic inflammatory disease. Also disclosed are processes for preparing these compounds and pharmaceutical compositions comprising these compounds.

Methods of treating cytokine mediated diseases

Disclosed are methods of treating certain cytokine mediated diseases or conditions using novel aromatic heterocyclic compounds of the formula(I) wherein Ar1,Ar2,L,Q and X are described herein.

Aromatic heterocyclic compounds as antiinflammatory agents

Disclosed are novel aromatic heterocyclic compounds of the formula(I) wherein Ar1,Ar2,L,Q and X are described herein. The compounds are useful in pharmaceutic compositions for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases. Also disclosed are processes of making such compounds.

Bis pyrazole-1H-pyrazole intermediates and their synthesis

Disclosed are aromatic heterocyclic compounds of the formula (I) wherein Ar1, Ar2, L, Q and X are described herein, and intermediate compounds useful for making such compounds. The compounds are useful in pharmaceutic compositions for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases. Also disclosed are processes of making compounds of the formula (I), their intermediates and processes of making such intermediates, including bis pyrazole-1H-pyrazole intermediates of the formula: wherein Alk, Rxand Rzare described herein.

Aromatic heterocyclic compound as antiinflammatory agents

Disclosed are novel aromatic heterocyclic compounds of the formula (I) wherein Ar1, Ar2, L, Q and X are described herein. The compounds are useful in pharmaceutic compositions for treating diseases or pathological conditions involving inflammation such as chronic inflammatory diseases. Also disclosed are processes of making such compounds.